EGFR and cancer: Furmonertinib, a novel third-generation EGFR-TKI, has shown promise in overcoming drug resistance mediated by the ATP-binding cassette transporters ABCB1 and ABCG2, which are central to the development of multidrug resistance in cancer patients receiving conventional chemotherapy.